Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Gluteal adipose-derived stem cell exosomes promote macrophage polarization and cartilage regeneration in osteoarthritis via PTPRC modulation.

Chen KT., Huang CC., Yadav VK., Pikatan NW., Fong IH., Kuo KT.

Animal Study on Osteoarthritis, Cartilage Damage, Meniscus Injury, Chronic Inflammation, published in Biomed Pharmacother (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biomed Pharmacother (2026)
Country
France
Reported sample size
—
Source database
PubMed
PMID
41740370
DOI
10.1016/j.biopha.2026.119130

Abstract (original English)

Osteoarthritis (OA) is a progressive joint disease characterized by cartilage degradation, synovial inflammation, and limited regenerative capacity. Adipose-derived stem cell exosomes (ADSC-Exo) represent a promising cell-free therapeutic approach due to their immunomodulatory properties. Gluteal ADSC-Exo were isolated and characterized by nanoparticle tracking analysis and Western blotting. Their effects were evaluated in vitro in human chondrocytes, fibroblast-like synoviocytes, and THP-1-derived macrophages using proliferation, migration, immunofluorescence, Seahorse metabolic analysis, and RNA sequencing. In vivo, OA was induced in mice by destabilization of the medial meniscus (DMM) and treated with ADSC-Exo, a protein tyrosine phosphatase receptor type C (PTPRC/CD45) inhibitor alone, or in combination. Cartilage pathology and inflammation were assessed by histology, Osteoarthritis Research Society International (OARSI) scoring, immunohistochemistry, and enzyme-linked immunosorbent assays. CRISPR/Cas9-mediated deletion of PTPRC was performed in M1-polarized macrophages to validate mechanistic involvement. ADSC-Exo enhanced cell proliferation, migration, and extracellular matrix gene expression while suppressing catabolic markers under inflammatory conditions. ADSC-Exo promoted macrophage polarization toward an anti-inflammatory M2 phenotype, reduced pro-inflammatory cytoki

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansMacrophagesExosomesOsteoarthritisRegenerationAdipose TissueMiceMaleStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research